Interleukin-7 (IL7) is an immune mediator known for its key role in the hematopoietic growth of T- and B-lymphocytes. IL7 is produced by various types of cells including keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells. Despite a theoretical anti-tumor effect, the aberrant expression of IL7 receptor (IL7R) in different types of cancer has been associated with poor prognosis (K. Suzuki, J Clin Oncol, 2013) and it has recently been demonstrated that IL7 and the presence of IL7R can have a pro-tumor effect in various cancers by decreasing cancer cell apoptosis or accelerating cell proliferation and lympho-vascular formation (J. Lin et al., Anticancer Research, 2017).
OSE-703 is a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7 (CD127), cytotoxic for human cells expressing CD127.
OSE-703, is currently being developed in partnership with the Memorial Sloan Kettering Cancer Center in New York to define its efficacy profile and potential development strategy.